AstraZeneca is Thursday's pick for IBD 50 Growth Stocks To Watch as the biopharmaceutical name is holding up relatively well ...

AstraZeneca PLC (NASDAQ:AZN – Get Free Report) has been given an average recommendation of “Buy” by the ten ratings firms that are currently covering the company, Marketbeat.com reports. One equities ...

This approval allows the use of Durvalumab in combination with Tremelimumab, broadening treatment options for patients ...

UBS analyst Matthew Weston maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £142.00. The ...

AstraZeneca’s share price has dropped recently on concerns relating to its Chinese operation, but this may have left the shares very undervalued. When investing, your capital is at risk.

AstraZeneca boasts a remarkably healthy drug portfolio and a pipeline of promising drugs in clinical development. Read why ...

The pharma giant has received the CDSCO nod to import sodium zirconium cyclosilicate powder for oral suspension (Lokelma) in ...

is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for the trailing 12 month period. Earnings Per Share (TTM ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

"Matterhorn is the first phase III trial of an immunotherapy to show a statistically significant improvement in event-free survival in patients with resectable gastric and gastroesophageal junction ...

AstraZeneca’s (LSE: AZN) share price remains significantly down from its 3 September 12-month traded high of £133.38. Such a drop could signal that the pharmaceuticals giant is fundamentally worth ...